Phenolic Profile of Nipa Palm Vinegar and Evaluation of Its Antilipidemic Activities

Obesity and overweight are strongly associated with dyslipidemia which can promote the development of cardiovascular diseases. Recently, natural products have been suggested as alternative compounds for antioxidant and antilipidemic activity. The objective of this study was to determine the phenolic compounds and assess the inhibitory activities on pancreatic lipase, cholesterol esterase, and cholesterol micellization of nipa palm vinegar (NPV). Total phenolic content was assessed and phenolic compounds were determined using the Folin–Ciocalteu assay and liquid chromatography-mass spectrometry (LC-MS), respectively. Pancreatic lipase and cholesterol esterase inhibitory activities of the NPV were measured using enzymatic colorimetric assays. The formation of cholesterol micelles was assessed using a cholesterol assay kit. The phenolic content of NPV was 167.10 ± 10.15 µg GAE/mL, and LC-MS analyses indicated the presence of gallic acid, isoquercetin, quercetin, catechin, and rutin as bioactive compounds. Additionally, the NPV inhibited pancreatic lipase and cholesterol esterase activities in a concentration-dependent manner. Moreover, the NPV also suppressed the formation of cholesterol micellization. These results suggest that phenolic compounds, especially gallic acid, isoquercetin, quercetin, catechin, and rutin, from NPV may be the main active compounds with possible cholesterol-lowering effects through inhibition of pancreatic lipase and cholesterol esterase activities as well as the inhibition of solubility of cholesterol micelles. Therefore, NPV may delay postprandial dyslipidemia, and it could be used as a natural source of bioactive compounds with antilipidemic activity. However, NPV should be extensively evaluated by animal and clinical human studies.


Introduction
Lipid metabolism disorders are commonly found in people who are obese. e prevalence of obesity and overweight has dramatically increased in developed and developing countries due to the increased consumption of high-fat diets and the daily intake of alcohol [1]. Obesity and overweight are associated with hyperglycemia and dyslipidemia in children and adolescents [2]. Dyslipidemia is a group of metabolic disorders and a noncommunicable disease manifested by elevation of serum cholesterol, low-density lipoprotein (LDL) cholesterol, and triglyceride concentrations and a decrease in high-density lipoprotein (HDL) cholesterol concentration. It is one of the major risk factors associated with atherosclerosis which leads to the development of cardiovascular diseases and increased mortality [3]. Orlistat is a weight loss agent which inhibits gastric and pancreatic lipases in the lumen of the gastrointestinal tract delaying absorption of dietary fat that is approved by the Food and Drug Administration for the treatment of obesity. It also improves total cholesterol and low-density lipoprotein for the treatment of dyslipidemia. e major side effects, which occur at an early stage of treatment with orlistat, are mainly gastrointestinal [4]. Simvastatin is a HMG-CoA reductase inhibitor which is commonly used to decrease blood cholesterol and triglyceride levels. e major adverse effects of statins are myositis, myalgia [5], rhabdomyolysis [6], and hepatic disorders [7].
Recently, natural products have been reported to have the potential to be developed faster and cheaper than conventional single drug. For example, curcumin, lycopene, monascin, ankaflavin, oleanolic acid, ursolic acid, berberine, amphene, tanshinone IIA, hesperetin, and naringenin inhibit cholesterol absorption in enterocytes [8]. us, natural products, especially phenolic compounds of these products, may inhibit pancreatic lipase, cholesterol esterase, and solubility of cholesterol micelles. Vinegar is generally used as a food condiment and as an alternative medicine for obesity [9], hyperlipidemia [10], hyperglycemia [11], and cancer [12] and as a disinfectant [13]. e nipa palm (Nypa fruticans Wurmb) vinegar has been used by Southeast Asia, and it has showed biological activities, such as antioxidant activity [14], antidiabetic activity [15], and hepatoprotective effects [16]. erefore, the NPV could be a natural alternative to treat common diseases from contemporary diet. Nevertheless, the antilipidemic activity of this vinegar has not been previously evaluated. is study aimed to investigate phenolic compounds and in vitro inhibitory effects on pancreatic lipase, cholesterol esterase, and cholesterol micellization of nipa palm vinegar.

Preparation of Nipa Palm
Vinegar. Nipa palm sap was collected from Pak Phanang District, Nakhon Si ammarat, ailand (8°12′25.1″ N, 100°14′51.7″ E). All parts of the nipa palm were authenticated and a voucher number (Nypa fruticans Wurmb, voucher no. 01518) was deposited at Botanic Garden, Walailak University, Nakhon Si ammarat, ailand. e nipa palm sap was collected from cut stalks. e nipa palm sap was fermented to nipa palm vinegar by the local traditional method. In brief, the collected nipa palm sap was placed in terracotta jars for 40 days at room temperature to allow the natural fermentation process to occur. e level of acidity of nipa palm vinegar reaches 4 to 5%.

Determination of Total Phenolic Content.
e total phenolic content was determined by the Folin-Ciocalteu assay as previously described [17]. In brief, 20 µL of each sample was mixed with 100 µL of Folin-Ciocalteu phenol reagent and 80 µl of sodium carbonate solution (75 g/L). After incubation for 30 min at room temperature, the absorbance was measured at 765 nm. A calibration curve was plotted using gallic acid solutions (31.25, 62.5, 125, 250, and 500 µg/mL). Total phenolic content was determined as µg gallic acid equivalent per ml of nipa palm vinegar (µg GAE/ mL).

Pancreatic Lipase Inhibition
Assay. Pancreatic lipase inhibition assay was undertaken as described by Adisakwattana et al. [19]. In brief, 25 µL of nipa palm vinegar diluted with distilled water, or positive control (orlistat), was mixed with 25 µL of porcine pancreatic lipase solution and 50 µL of oleate ester of 0.1 mM fluorescent 4-methylumbelliferone (4-MUO) solution in phosphate buffer saline, subsequently. e mixture was incubated at 37 o C for 20 min. Reaction was stopped by adding 100 µL of 0.1 M sodium citrate at pH 4.2. e fluorescence of 4-methylumbelliferone released by the lipase was measured at excitation and emission wavelengths of 320 and 450 nm, respectively. Control without sample or orlistat represented 100% pancreatic lipase (PL) activity. e tests were performed in triplicate.

Pancreatic Cholesterol Esterase Inhibition Assay.
e pancreatic cholesterol esterase inhibition assay was performed according to a previously published method [20]. In brief, different concentrations of nipa palm vinegar were incubated with mixtures containing 5.16 mM taurocholic acid, 0.2 mM p-nitrophenylbutyrate (p-NPB) in 100 mM sodium phosphate buffer, and 100 mM NaCl at pH 7.0. Porcine pancreatic cholesterol esterase at concentration of 1 µg/mL was added into the reaction tube, and samples were incubated at 25°C for 5 min. After that, the absorbance of the solutions was measured at 450 nm. Simvastatin served as a positive control. Results were based on triplicate analysis.

Cholesterol Micellization Assay.
Cholesterol micelles served as a model system for in vitro cholesterol micellization and were prepared according to a previous method [21]. In brief, the micelle solution (2 mM cholesterol, 1 mM oleic acid, and 2.4 mM phosphatidylcholine) was dissolved in methanol and then dried under nitrogen. After that, 15 mM phosphate-buffered saline (PBS) solution containing 6.6 mM taurocholate salt, pH 7.4, was added onto the dried micelles. e emulsion was sonicated twice for 30 min using a sonicator. e micelle solution was incubated overnight at 37°C. Various concentrations of nipa palm vinegar or equivalent PBS as a control were added into the micelle solutions, and samples were incubated for 2 h at 37°C. is mixture was then centrifuged at 16,000 rpm for 20 min. e supernatant of the mixture was collected for determination of cholesterol using total cholesterol test kits (Human Diagnostics Worldwide, Weisbaden, Germany). Gallic acid served as a positive control. All tests were taken in triplicate analysis.

Data Analysis.
All analyses were carried out in triplicate, and data are expressed as mean ± standard deviation. e correlation coefficient (R 2 ) was evaluated by using SigmaPlot version 12.2 software.

Determination of Total Phenolic Content.
e amount of total phenolics in nipa palm vinegar (NPV) was determined using the Folin-Ciocalteu method.
e value was determined as µg gallic acid equivalent per ml of NPV (µg GAE/ mL). e phenolic content of NPV was determined to be 167.10 ± 10.15 µg GAE/mL.

Pancreatic Lipase Inhibitory Activity of Nipa Palm
Vinegar.
e inhibitory activity of nipa palm vinegar against pancreatic lipase is shown in Figure 2. e nipa palm vinegar inhibited pancreatic lipase activity by 9.55, 12.51, 19.65, 28.14, 50.53, and 60.22% at concentrations of 3.13, 6.25, 12.50, 25.00, 50.00, and 100.00 µL/mL, respectively. e nipa palm vinegar had an IC 50 value of 69.95 µL/mL. Orlistat served as a pancreatic lipase inhibitor control, and a concentration of 2 µg/mL reduced activity by 53.67%. ese results show that the NPV showed a lipase inhibiting activity.  (Figure 3). Simvastatin at a concentration of 300 µg/mL was used as a positive control which inhibited cholesterol esterase by 41.66%. ese findings show that the NPV has the ability to inhibit cholesterol esterase in a dose-dependent manner. Figure 4. e NPV suppressed cholesterol micellization by 13.46, 19.23, 25.00, 38.46, and 46.15% at concentrations of 12.50, 25.00, 50.00, 100.00, and 200.00 µL/mL, respectively. Gallic acid at a concentration of 200 µg/mL was used as a positive control which inhibited cholesterol micellization by 84.62%. ese results show that the NPV can inhibit the formation of cholesterol micellization in a dose-dependent manner.

Correlation Analyses of Pancreatic Lipase Inhibition, Pancreatic Cholesterol Esterase Inhibition, and Cholesterol Micellization Inhibition of Nipa Palm Vinegar.
e linear regression analysis and correlation coefficients between the variables are presented in Figure 5.

Discussion
Dyslipidemia is a key risk factor in the development of cardiovascular diseases which leads to increased morbidity and mortality [8]. Natural products have been used as an alternative medicine for the prevention and management of cardiovascular diseases [22]. ere are many risk factors for dyslipidemia including genetic factors, hormonal abnormalities, and lifestyle factors. A diet especially high in fat is believed to be one of the greatest risk factors for the development of dyslipidemia [23]. Normally, pancreatic lipase is a key enzyme that hydrolyses ester linkages of triglyceride [24]. erefore, pancreatic lipase inhibition is a goal to reduce fat absorption to control dyslipidemia. Pancreatic cholesterol esterase is an enzyme which hydrolyses cholesterol esters, so inhibition of pancreatic cholesterol esterase can reduce cholesterol absorption and may be useful for therapeutics for controlling cholesterol [25]. Moreover, the reduction of micelle formation is a target for lowering blood cholesterol level [21]. is study evaluated nipa palm vinegar for its total phenolic content and the presence of phenolic compounds as well as determined its ability to inhibit pancreatic lipase, inhibit cholesterol esterase, and inhibit cholesterol micellization.

Evidence-Based Complementary and Alternative Medicine
Orlistat is a well-known pancreatic lipase inhibitor which is produced from Streptomyces toxytricini. It reacts with lipases at the active site serine by forming a covalent bond and thus inactivating the ability of these enzymes to hydrolyse dietary fat in the small intestine [35]. Adverse effects of orlistat are liquid stools, steatorrhea, fecal urgency, incontinence, flatulence, abdominal cramping, and fat-soluble vitamin deficiencies [36]. Recently, many researchers have been focused on the effects of natural products for the treatment of dyslipidemia [37]. Our study determined the inhibitory activity of NPV towards pancreatic lipase, and the results showed that NPV can inhibit pancreatic lipase in a concentration-dependent manner with an IC 50 value of 69.95 µL/mL. In a previous study, an aqueous extract of NPV was able to significantly reduce blood glucose in streptozotocin-induced diabetic rats [15]. e aqueous extract of NPV also stimulated insulin secretion in RIN-5F cells [16]. Moreover, nipa palm sap and its syrup inhibited α-glucosidase which hydrolyses polysaccharides [38].
Pancreatic cholesterol esterase exerts important functions in controlling the bioavailability of cholesterol from dietary cholesterol esters, contributing to the incorporation of cholesterol into mixed micelles, and in helping to transport free cholesterol to enterocytes [25]. It has previously been reported that inhibition of pancreatic cholesterol esterase and the solubility of cholesterol micelles by gallic acid, catechin, and epicatechin from grape seed extract results in delaying the absorption of cholesterol [20]. e current findings revealed that NPV inhibited pancreatic cholesterol esterase and the solubility of cholesterol micelles in a concentration-dependent manner. ere was a positive correlation between pancreatic lipase inhibition and pancreatic cholesterol esterase inhibition. Moreover, cholesterol micellization inhibition had a positive correlation with pancreatic lipase inhibition and pancreatic cholesterol esterase inhibition. erefore, it could be hypothesized that the NPV can inhibit pancreatic cholesterol esterase and may protect against cholesterol micellization.
ere are several reports demonstrating anti-dyslipidemia activity of natural compounds. Gallic acid has been reported to decrease levels of serum triglycerides, total cholesterol, and low-density lipoprotein in high-fat induced dyslipidemia in rats [39]. Similarly, quercetin had a strong inhibitory activity on pancreatic lipase [40], and it also reduced serum levels of triglycerides and cholesterol in a rabbit model of high-fat diet-induced atherosclerosis [41]. Moreover, isoquercetin, a glucoside derivative of quercetin, improved hepatic lipid accumulation through activating the AMPK pathway and inhibiting TGF-β signalling in a highfat diet-induced nonalcoholic fatty liver disease rat model [42]. A previous study showed that green tea catechin suppressed cholesterol absorption in the small intestine and reduced serum cholesterol concentrations [43]. Other studies have also demonstrated the antiobesity effects of rutin by decreasing serum lipid profiles and leptin [44].
According to our in vitro finding, it can be hypothesized that phenolic compounds including gallic acid, isoquercetin, quercetin, catechin, and rutin from NPV may be the main active compounds with possible cholesterol-lowering effects through inhibition of pancreatic lipase and cholesterol esterase activities as well as the inhibition of solubility of cholesterol micelles. More in vivo studies in animal and clinical human studies are required to determine the antidyslipidemia activity of NPV and to confirm its mechanism for the aim of application in the prevention and treatment of dyslipidemia.

Conclusion
Our results indicate that nipa palm vinegar may delay the digestion of a high-fat diet and absorption through small intestine through mechanisms such as the inhibition of pancreatic lipase and cholesterol esterase activities as well as through the inhibition of solubility of cholesterol micelles.
ese results indicate that NPV could be used as a natural source of bioactive compounds with antilipidemic activity. Nevertheless, NPV should be extensively evaluated by animal and clinical human studies.

Data Availability
e data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
e authors declare that they have no conflicts of interest.